{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0006397\nAge: 89\nGender: Female\nSample ID: P-0006397-T01-IM5\nGene Panel: IMPACT410\nCancer Type: Lung Adenocarcinoma\nSample Type: Primary\nTumor Purity: 20.0%\n=============\nDNA Variants:\nBRAF c.1799T>A (p.V600E) - in 5.00% of 595 reads\nTP53 c.548C>G (p.S183*) - in 6.00% of 741 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Non-small cell lung cancer (NSCLC)\",\n    \"Disease Phase or Condition\": \"Locally advanced or metastatic disease with EGFR exon 19 deletion\",\n    \"Drug Name\": \"Cisplatin + Osimertinib + Pemetrexed\",\n    \"Prior Treatment or Resistance Status\": \"Progressed on or after platinum-based chemotherapy\",\n    \"Genomic Features\": \"EGFR exon 19 deletion\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf\"\n  }\n}"
}